JP6907188B2 - 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管 - Google Patents

接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管 Download PDF

Info

Publication number
JP6907188B2
JP6907188B2 JP2018506180A JP2018506180A JP6907188B2 JP 6907188 B2 JP6907188 B2 JP 6907188B2 JP 2018506180 A JP2018506180 A JP 2018506180A JP 2018506180 A JP2018506180 A JP 2018506180A JP 6907188 B2 JP6907188 B2 JP 6907188B2
Authority
JP
Japan
Prior art keywords
blood collection
plasma
subject
contact system
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018506180A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018532100A5 (https=
JP2018532100A (ja
Inventor
セクストン，ダニエル，ジェー．
フォーセット，リヤン
Original Assignee
ダイアックス コーポレーション
ダイアックス コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダイアックス コーポレーション, ダイアックス コーポレーション filed Critical ダイアックス コーポレーション
Publication of JP2018532100A publication Critical patent/JP2018532100A/ja
Publication of JP2018532100A5 publication Critical patent/JP2018532100A5/ja
Priority to JP2021109554A priority Critical patent/JP7242765B2/ja
Application granted granted Critical
Publication of JP6907188B2 publication Critical patent/JP6907188B2/ja
Priority to JP2023035922A priority patent/JP2023078232A/ja
Priority to JP2024123778A priority patent/JP7829634B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/508—Rigid containers without fluid transport within
    • B01L3/5082—Test tubes per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150015—Source of blood
    • A61B5/15003—Source of blood for venous or arterial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150755—Blood sample preparation for further analysis, e.g. by separating blood components or by mixing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/153—Devices specially adapted for taking samples of venous or arterial blood, e.g. with syringes
    • A61B5/154—Devices using pre-evacuated means
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/16—Reagents, handling or storing thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0832—Geometry, shape and general structure cylindrical, tube shaped
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Clinical Laboratory Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018506180A 2015-08-13 2016-08-12 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管 Active JP6907188B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021109554A JP7242765B2 (ja) 2015-08-13 2021-06-30 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管
JP2023035922A JP2023078232A (ja) 2015-08-13 2023-03-08 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管
JP2024123778A JP7829634B2 (ja) 2015-08-13 2024-07-30 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562204644P 2015-08-13 2015-08-13
US62/204,644 2015-08-13
US201562214308P 2015-09-04 2015-09-04
US62/214,308 2015-09-04
PCT/US2016/046681 WO2017027771A1 (en) 2015-08-13 2016-08-12 Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021109554A Division JP7242765B2 (ja) 2015-08-13 2021-06-30 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管

Publications (3)

Publication Number Publication Date
JP2018532100A JP2018532100A (ja) 2018-11-01
JP2018532100A5 JP2018532100A5 (https=) 2019-09-05
JP6907188B2 true JP6907188B2 (ja) 2021-07-21

Family

ID=56802683

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018506180A Active JP6907188B2 (ja) 2015-08-13 2016-08-12 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管
JP2021109554A Active JP7242765B2 (ja) 2015-08-13 2021-06-30 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管
JP2023035922A Pending JP2023078232A (ja) 2015-08-13 2023-03-08 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管
JP2024123778A Active JP7829634B2 (ja) 2015-08-13 2024-07-30 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021109554A Active JP7242765B2 (ja) 2015-08-13 2021-06-30 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管
JP2023035922A Pending JP2023078232A (ja) 2015-08-13 2023-03-08 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管
JP2024123778A Active JP7829634B2 (ja) 2015-08-13 2024-07-30 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管

Country Status (13)

Country Link
US (3) US10870115B2 (https=)
EP (3) EP3909509B1 (https=)
JP (4) JP6907188B2 (https=)
KR (2) KR102777762B1 (https=)
CN (2) CN116196995A (https=)
AU (2) AU2016306653B2 (https=)
BR (1) BR112018002742B1 (https=)
CO (1) CO2018002531A2 (https=)
EA (1) EA201890478A1 (https=)
ES (1) ES2938089T3 (https=)
IL (3) IL295914B2 (https=)
MX (2) MX2018001786A (https=)
WO (1) WO2017027771A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6907188B2 (ja) 2015-08-13 2021-07-21 ダイアックス コーポレーション 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管
US11340237B2 (en) 2016-09-16 2022-05-24 Takeda Pharmaceutical Company Limited Metabolite biomarkers for diseases associated with the contact activation system
EP4548103A2 (en) 2022-06-30 2025-05-07 Takeda Pharmaceutical Company Limited Protein biomarkers for lanadelumab treatment

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047323A (en) 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
WO1995021601A2 (en) 1994-01-11 1995-08-17 Protein Engineering Corporation Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
JP3622286B2 (ja) * 1995-09-01 2005-02-23 日東紡績株式会社 α２ −プラスミンインヒビタ−の測定方法及び測定試 薬
US5789261A (en) * 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
SK12572001A3 (sk) * 1999-03-15 2002-03-05 Takeda Chemical Industries, Ltd. Proteín, peptid, protilátka, spôsob výroby a farmaceutický prostriedok
JP4496407B2 (ja) 2002-05-13 2010-07-07 ベクトン・ディキンソン・アンド・カンパニー プロテアーゼ阻害剤試料採取システム
SE0202880D0 (sv) * 2002-07-26 2002-09-30 Wieslab Ab Complement system deficiency assay
US8603345B2 (en) * 2003-02-13 2013-12-10 Becton, Dickinson And Company Devices for component removal during blood collection, and uses thereof
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
US20050124965A1 (en) * 2003-12-08 2005-06-09 Becton, Dickinson And Company Phosphatase inhibitor sample collection system
WO2005084317A2 (en) * 2004-03-01 2005-09-15 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
EP1828152B1 (en) 2004-12-08 2008-08-20 Bristol-Myers Squibb Company Heterocyclic compounds as inhibitors of factor viia
US20060183771A1 (en) 2005-02-17 2006-08-17 Seiffert Dietmar A Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
ES2336622T3 (es) 2006-06-06 2010-04-14 F. Hoffmann-La Roche Ag Recipiente de recogida de sangre total lista para usar.
EP1890155A1 (en) * 2006-08-17 2008-02-20 F. Hoffmann-Roche AG Methods and means for determining platelet function and diagnosing platelet-related and cardiovascular disorders
US20080286818A1 (en) * 2007-05-18 2008-11-20 Datwyler Saul A Blood sample handling methods for improved assays for myeloperoxidase
JP2010528647A (ja) * 2007-06-06 2010-08-26 ドマンティス リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト
WO2009022001A1 (en) * 2007-08-16 2009-02-19 Novartis Ag Improvement of drug tolerance in immunogenicity testing
WO2009026539A1 (en) * 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
US8283160B2 (en) * 2007-09-11 2012-10-09 Frey Ii William H Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
US9482677B2 (en) 2008-02-27 2016-11-01 Scios Inc. Method, composition and device for sampling natriuretic peptides in a biological fluid
US7985188B2 (en) 2009-05-13 2011-07-26 Cv Holdings Llc Vessel, coating, inspection and processing apparatus
WO2011024172A2 (en) * 2009-08-27 2011-03-03 Technion Research & Development Foundation Ltd. Liposomal compositions and uses of same
WO2011033046A1 (en) 2009-09-18 2011-03-24 Probiodrug Ag Novel assay for the detection of amyloid beta peptides
CN102740888B (zh) * 2009-11-24 2016-10-12 奥尔德生物制药公司 Il-6抗体及其用途
NZ609363A (en) 2010-10-18 2015-04-24 Nestec Sa Methods for determining anti-drug antibody isotypes
KR102320178B1 (ko) * 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
CA2828761C (en) 2011-03-04 2017-04-04 Becton, Dickinson And Company Blood collection device containing lysophospholipase inhibitor
JP6189754B2 (ja) * 2011-03-04 2017-08-30 イントレキソン コーポレーション タンパク質を条件的に発現するベクター
US9352016B2 (en) * 2011-03-09 2016-05-31 Csl Behring Gmbh Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces
GB201114017D0 (en) 2011-08-15 2011-09-28 Univ Dundee Inhibitors against endosomal/ysosomal enzymes
BR112014018970A8 (pt) * 2012-02-02 2017-07-11 Becton Dickinson Co Dispositivos de coleta de amostra com agentes de estabilização sanguínea
RU2015136025A (ru) 2013-02-01 2017-03-06 Бектон, Дикинсон энд Кампани Устройства для сбора крови, содержащие добавки, ингибирующие контактный путь свертывания крови
CA2916399C (en) 2013-06-28 2022-08-02 Marc Nolte Combination therapy using a factor xii inhibitor and a c1-inhibitor
WO2015061183A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
JP6907188B2 (ja) * 2015-08-13 2021-07-21 ダイアックス コーポレーション 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管

Also Published As

Publication number Publication date
JP7829634B2 (ja) 2026-03-13
CN108135547A (zh) 2018-06-08
JP7242765B2 (ja) 2023-03-20
JP2023078232A (ja) 2023-06-06
NZ739623A (en) 2023-09-29
US20190022641A1 (en) 2019-01-24
EP4574040A2 (en) 2025-06-25
AU2021215261B2 (en) 2023-10-12
EA201890478A1 (ru) 2018-07-31
IL257209B (en) 2022-09-01
IL311909B1 (en) 2025-11-01
HK1255461A1 (en) 2019-08-16
WO2017027771A1 (en) 2017-02-16
CO2018002531A2 (es) 2018-06-12
EP3334343B1 (en) 2022-10-19
KR102777762B1 (ko) 2025-03-11
IL295914B1 (en) 2024-05-01
KR20250035045A (ko) 2025-03-11
US20230182139A1 (en) 2023-06-15
JP2024150720A (ja) 2024-10-23
BR112018002742B1 (pt) 2023-05-16
EP3909509A1 (en) 2021-11-17
EP4574040A3 (en) 2025-08-27
ES2938089T3 (es) 2023-04-04
AU2016306653A1 (en) 2018-02-22
CN108135547B (zh) 2023-01-10
IL257209A (en) 2018-04-30
MX2022014713A (es) 2022-12-16
US10870115B2 (en) 2020-12-22
IL311909B2 (en) 2026-03-01
IL311909A (en) 2024-06-01
MX2018001786A (es) 2018-06-06
US11826758B2 (en) 2023-11-28
EP3909509B1 (en) 2025-04-09
EP3334343A1 (en) 2018-06-20
US11458477B2 (en) 2022-10-04
IL295914B2 (en) 2024-09-01
AU2016306653B2 (en) 2021-05-13
CN116196995A (zh) 2023-06-02
US20210322972A1 (en) 2021-10-21
AU2021215261A1 (en) 2021-09-02
BR112018002742A2 (https=) 2018-10-02
CA2995457A1 (en) 2017-02-16
JP2018532100A (ja) 2018-11-01
JP2021164678A (ja) 2021-10-14
IL295914A (en) 2022-10-01
KR20180100107A (ko) 2018-09-07

Similar Documents

Publication Publication Date Title
JP7829634B2 (ja) 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管
AU2014336122A1 (en) Method for diagnosis of primary hyperaldosteronism
CN104395750A (zh) 测量血液样品中蛋白水解级联的肽降解产物的方法
HK40128524A (en) Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
CA2995457C (en) Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
HK40061902A (en) Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
HK1255461B (en) Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
KR101885946B1 (ko) 제2형 당뇨병 진단용 마커 및 그 용도
HK40061902B (en) Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
EA040036B1 (ru) Вакуумные пробирки для сбора крови, содержащие ингибиторы протеазы, для оценки активации контактной системы
NZ739623B2 (en) Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190724

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200609

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210601

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210630

R150 Certificate of patent or registration of utility model

Ref document number: 6907188

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250